Compare Regeneron Pharmaceuticals Inc (REGN) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Taskus Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Taskus Inc trades at $5.76 (market cap $534.36M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 132.5× Taskus Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| REGN | TASK | |
|---|---|---|
Market Cap | $70.79B | $534.36M |
Sector | Health | Technology |
52-Week High | $812.27 | $18.21 |
52-Week Low | $545.46 | $4.57 |
Enterprise Value | $64.74B | $930.06M |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
TaskUs (TASK) trades at $5.84, up 0.17% with a bullish technical signal. The company shows strong fundamentals with a P/E of 5.14 and net income margin of 8.7%, supported by recent CFO appointment and positive survey on robotaxi adoption. Revenue grew to $1.18B in 2025, and cash flow remains positive.
Outlook is positive with a consensus price target of $9.50, indicating 63% upside. Risks include recent Q1 2026 earnings miss and competitive pressures. Analyst sentiment is bullish with 55% buy ratings, but high RSI levels suggest caution near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
